SI2805723T1 - Cladribine regimen for the treatment of multiple sclerosis - Google Patents
Cladribine regimen for the treatment of multiple sclerosis Download PDFInfo
- Publication number
- SI2805723T1 SI2805723T1 SI200532191T SI200532191T SI2805723T1 SI 2805723 T1 SI2805723 T1 SI 2805723T1 SI 200532191 T SI200532191 T SI 200532191T SI 200532191 T SI200532191 T SI 200532191T SI 2805723 T1 SI2805723 T1 SI 2805723T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cladribine
- tablets
- use according
- months
- period
- Prior art date
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title claims abstract 40
- 229960002436 cladribine Drugs 0.000 title claims abstract 40
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract 7
- 238000011282 treatment Methods 0.000 claims abstract 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims abstract 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims abstract 2
- 230000006698 induction Effects 0.000 claims 10
- 238000012423 maintenance Methods 0.000 claims 6
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| EP14001970.4A EP2805723B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2805723T1 true SI2805723T1 (en) | 2018-02-28 |
Family
ID=36227798
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200532191T SI2805723T1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for the treatment of multiple sclerosis |
| SI200532305T SI3332789T1 (sl) | 2004-12-22 | 2005-12-20 | Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze |
| SI200532321T SI4070800T1 (sl) | 2004-12-22 | 2005-12-20 | Režim kladribina za zdravljenje multiple skleroze |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200532305T SI3332789T1 (sl) | 2004-12-22 | 2005-12-20 | Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze |
| SI200532321T SI4070800T1 (sl) | 2004-12-22 | 2005-12-20 | Režim kladribina za zdravljenje multiple skleroze |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (https=) |
| EP (7) | EP2275110B1 (https=) |
| JP (7) | JP5795456B2 (https=) |
| KR (1) | KR20070091662A (https=) |
| AR (1) | AR052830A1 (https=) |
| AU (2) | AU2005318190B2 (https=) |
| BR (1) | BRPI0517132B8 (https=) |
| CA (2) | CA3087419C (https=) |
| CY (3) | CY1112614T1 (https=) |
| DK (3) | DK2805723T3 (https=) |
| EA (1) | EA015799B1 (https=) |
| ES (2) | ES3007339T3 (https=) |
| FI (1) | FI4070800T3 (https=) |
| FR (1) | FR18C1008I2 (https=) |
| HR (1) | HRP20120228T1 (https=) |
| HU (3) | HUE059133T2 (https=) |
| IL (2) | IL183930A0 (https=) |
| LT (3) | LT4070800T (https=) |
| LU (1) | LUC00064I2 (https=) |
| MX (1) | MX2007007610A (https=) |
| NO (1) | NO20073813L (https=) |
| PL (4) | PL1827461T3 (https=) |
| SG (1) | SG160391A1 (https=) |
| SI (3) | SI2805723T1 (https=) |
| WO (1) | WO2006067141A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275110B1 (en) | 2004-12-22 | 2013-07-10 | Merck Serono SA | Cladribine regimen for treating Multiple Sclerosis |
| WO2007135172A2 (en) | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| AR113906A1 (es) * | 2017-11-24 | 2020-06-24 | Merck Patent Ges Mit Beschraenkter Haftung | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple |
| BR112023003432A2 (pt) | 2020-09-10 | 2023-03-21 | Merck Patent Gmbh | Regime de tratamento para o tratamento de doenças autoimunes |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| EP0801571B1 (en) | 1994-12-22 | 2002-09-04 | Ortho Pharmaceutical Corporation | Soluble 2-chloro-2'-deoxyadenosine formulations |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| EP1556400B1 (en) | 2002-09-25 | 2013-05-01 | Brigham Young University | Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| WO2004075903A1 (en) * | 2003-02-25 | 2004-09-10 | Applied Research Systems Ars Holding N.V. | Combined use of ribavirin and interferon beta in demyelinating diseases |
| DK2272503T3 (da) | 2003-03-28 | 2013-05-21 | Ares Trading Sa | Orale formuleringer af cladribin |
| WO2004087100A2 (en) | 2003-03-28 | 2004-10-14 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| EP2275110B1 (en) | 2004-12-22 | 2013-07-10 | Merck Serono SA | Cladribine regimen for treating Multiple Sclerosis |
| WO2007135172A2 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Revoked
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en not_active Withdrawn
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2805723T1 (en) | Cladribine regimen for the treatment of multiple sclerosis | |
| ES2693085T1 (es) | Uso de estriol en bajas dosis | |
| CA2633594C (en) | Means and methods for the treatment of tumorous diseases | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| BR112012009857A2 (pt) | composições farmacêuticas sólidas contendo um inibidor de integrase | |
| GB0423653D0 (en) | Pharmaceutical compounds | |
| BRPI0620185B8 (pt) | formulação farmacêutica, comprimidos, e, processo para a preparação de uma formulação farmacêutica | |
| GEP20104994B (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
| ZA202408030B (en) | Tricyclic heterocyclic derivatives, compositions and uses thereof | |
| NO20070681L (no) | 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft | |
| BR0307441A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade | |
| WO2007047327A3 (en) | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency | |
| EA200400664A1 (ru) | Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii | |
| SI1983984T1 (en) | Treatment of tuberous sclerosis | |
| TNSN08173A1 (en) | Dispersible tablets comprising deferasirox | |
| BR0211198A (pt) | Composições farmacêuticas e seu uso | |
| WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
| MX2025012818A (es) | Derivados de heterociclicos triciclicos, composiciones y usos de estos | |
| CA2563058C (en) | Supportive treatment of liver disease | |
| MX354080B (es) | Tratamiento de la esclerosis multiple (em) con campath 1h. | |
| UA95253C2 (ru) | Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит | |
| WO2007145993A3 (en) | Modified compositions and methods for enhancing brain function | |
| CN104666415A (zh) | 包含土霉素和中药提取物的复方制剂 | |
| BRPI0413458A (pt) | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
| Pandey et al. | Hepatogenic effect of Livol, Eclipta alba and Silybum marianum on paracetamol induced liver damage in rabbits |